Tenet Healthcare (NYSE:THC) Price Target Raised to $265.00

Tenet Healthcare (NYSE:THC) had its price objective hoisted by investment analysts at Mizuho from $235.00 to $265.00 in a research report issued on Thursday,Benzinga reports. The firm presently has an “outperform” rating on the stock. Mizuho’s target price points to a potential upside of 12.90% from the company’s previous close.

THC has been the subject of several other research reports. Wells Fargo & Company reaffirmed an “overweight” rating and issued a $265.00 price objective on shares of Tenet Healthcare in a research report on Monday, February 16th. Jefferies Financial Group raised their price target on shares of Tenet Healthcare from $250.00 to $265.00 and gave the company a “buy” rating in a report on Thursday, February 12th. KeyCorp boosted their price objective on shares of Tenet Healthcare from $225.00 to $250.00 and gave the stock an “overweight” rating in a report on Thursday, February 12th. Leerink Partners raised their target price on Tenet Healthcare from $255.00 to $264.00 and gave the company an “outperform” rating in a research note on Friday, February 20th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Tenet Healthcare in a research note on Wednesday, March 4th. One analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat.com, Tenet Healthcare has an average rating of “Moderate Buy” and a consensus target price of $249.89.

Tenet Healthcare Stock Down 1.1%

Shares of NYSE THC opened at $234.73 on Thursday. The stock has a fifty day moving average price of $212.38 and a 200 day moving average price of $203.51. The company has a current ratio of 1.76, a quick ratio of 1.68 and a debt-to-equity ratio of 2.18. Tenet Healthcare has a 12-month low of $109.82 and a 12-month high of $247.21. The company has a market cap of $20.41 billion, a P/E ratio of 15.15, a P/E/G ratio of 1.17 and a beta of 1.39.

Tenet Healthcare (NYSE:THC) last issued its earnings results on Wednesday, February 11th. The company reported $4.70 earnings per share for the quarter, topping the consensus estimate of $4.08 by $0.62. The company had revenue of $5.53 billion during the quarter, compared to the consensus estimate of $5.47 billion. Tenet Healthcare had a return on equity of 26.33% and a net margin of 6.60%.The company’s revenue was up 8.9% compared to the same quarter last year. During the same quarter in the prior year, the business earned $3.44 earnings per share. Tenet Healthcare has set its FY 2026 guidance at 16.190-18.470 EPS. Research analysts anticipate that Tenet Healthcare will post 12.24 EPS for the current fiscal year.

Insider Activity

In other news, Director Nadja West sold 2,178 shares of the stock in a transaction dated Monday, December 15th. The shares were sold at an average price of $197.47, for a total transaction of $430,089.66. Following the transaction, the director owned 28,480 shares of the company’s stock, valued at approximately $5,623,945.60. This trade represents a 7.10% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider R. Scott Ramsey sold 8,017 shares of the business’s stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $232.70, for a total value of $1,865,555.90. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 42,195 shares of company stock worth $9,823,406. 0.81% of the stock is currently owned by corporate insiders.

Institutional Trading of Tenet Healthcare

Institutional investors and hedge funds have recently modified their holdings of the business. Price T Rowe Associates Inc. MD boosted its holdings in shares of Tenet Healthcare by 1.6% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 7,490,350 shares of the company’s stock valued at $1,488,484,000 after buying an additional 119,809 shares during the period. Boston Partners lifted its holdings in Tenet Healthcare by 15.7% in the fourth quarter. Boston Partners now owns 3,642,136 shares of the company’s stock worth $723,804,000 after acquiring an additional 494,581 shares during the last quarter. AQR Capital Management LLC grew its holdings in shares of Tenet Healthcare by 20.3% during the fourth quarter. AQR Capital Management LLC now owns 2,256,539 shares of the company’s stock valued at $448,419,000 after purchasing an additional 380,116 shares during the last quarter. Ameriprise Financial Inc. lifted its holdings in shares of Tenet Healthcare by 8.0% in the 2nd quarter. Ameriprise Financial Inc. now owns 2,119,423 shares of the company’s stock worth $373,020,000 after purchasing an additional 157,109 shares during the last quarter. Finally, Norges Bank acquired a new position in Tenet Healthcare during the 4th quarter valued at approximately $248,494,000. 95.44% of the stock is owned by institutional investors and hedge funds.

About Tenet Healthcare

Tenet Healthcare Corporation (NYSE: THC) is a diversified American healthcare services company that owns and operates acute care hospitals and a broad range of outpatient facilities. Its portfolio includes general acute-care hospitals, specialty hospitals, ambulatory surgery centers, urgent care and diagnostic imaging centers, and other ancillary service locations. Tenet’s operations are oriented around delivering inpatient and outpatient clinical care across multiple medical specialties, with an emphasis on surgical services, emergency care, and advanced diagnostics.

In addition to facility-based care, Tenet provides integrated services designed to support clinical operations and improve patient access and care coordination.